Development and Validation of a Deep Learning-Based Survival Prediction Model for Pediatric Glioma Patients: A Retrospective Study Using the SEER Database and Chinese Data

Glioma Clinical Trial

Official title:

Development and Validation of a Deep Learning-Based Survival Prediction Model for Pediatric Glioma Patients: A Retrospective Study Using the SEER Database and Chinese Data

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06199388
• Other study ID #: TDLL-202312-05
• Status: Completed
• Start date: September 20, 2022
• Est. completion date: December 20, 2023

Study information

• Verified date: December 2023
• Source: Tang-Du Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Accurately predicting the survival of pediatric glioma patients is crucial for informed clinical decision-making and selecting appropriate treatment strategies. However, there is a lack of prognostic models specifically tailored for pediatric glioma patients. This study aimed to address this gap by developing a time-dependent deep learning model to aid physicians in making more accurate prognostic assessments and treatment decisions.

Description:

This retrospective study focuses on survival prediction in pediatric glioma patients using a population-based approach. The model was trained using the Surveillance, Epidemiology, and End Results (SEER) Registry database. To identify specific tumor types, the International Classification of Diseases for Oncology, 3rd Edition codes (ICD-O-3) were used, including codes 9450, 9394, 9421, 9384, 9383, 9424, 9400, 9420, 9410, 9411, 9380, 9382, 9391, 9393, 9390, 9401, 9381, 9451, 9440, 9441, 9442, 9430, and 9380, covering astrocytic tumors, oligodendroglia tumors, oligoastrocytic tumors, ependymal tumors, and other gliomas. Inclusion criteria comprised all primary brain tumors (C71.0-C71.9, C72.3, C72.8, C75.3) diagnosed between 2000 and 2018, among patients under 21 years old, and meeting the third edition of the ICD-O-3 classification. Only patients with available survival time were included, and those with unknown or missing clinical features were excluded. This cohort consisted of 258 pediatric glioma patients diagnosed at Tangdu Hospital in Xi'an, China, between January 2010 and December 2018. These patients had complete clinical data and comprehensive follow-up records.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9532
• Est. completion date: December 20, 2023
• Est. primary completion date: August 16, 2023
• Gender: All
• Age group: N/A to 21 Years

Eligibility

Inclusion Criteria:

• To identify specific tumor types, the International Classification of Diseases for Oncology, 3rd Edition codes (ICD-O-3) were used, including codes 9450, 9394, 9421, 9384, 9383, 9424, 9400, 9420, 9410, 9411, 9380, 9382, 9391, 9393, 9390, 9401, 9381, 9451, 9440, 9441, 9442, 9430, and 9380, covering astrocytic tumors, oligodendroglia tumors, oligoastrocytic tumors, ependymal tumors, and other gliomas. Inclusion criteria comprised all primary brain tumors (C71.0-C71.9, C72.3, C72.8, C75.3) diagnosed, among patients under 21 years old, and meeting the third edition of the ICD-O-3 classification.

Exclusion Criteria:

• Only patients with available survival time were included, and those with unknown or missing clinical features were excluded.

Related Conditions & MeSH terms

• Glioma

Intervention

Other:
• Survival state
We recorded clinically relevant information and survival status of pediatric glioma patients

Locations

Country	Name	City	State
China	Tangdu Hospital	Xi'an	Shannxi

Sponsors (1)

Lead Sponsor	Collaborator
Tang-Du Hospital

Country where clinical trial is conducted

China, 

References & Publications (2)

Doll KM, Rademaker A, Sosa JA. Practical Guide to Surgical Data Sets: Surveillance, Epidemiology, and End Results (SEER) Database. JAMA Surg. 2018 Jun 1;153(6):588-589. doi: 10.1001/jamasurg.2018.0501. No abstract available. — View Citation

Thomas L, Li F, Pencina M. Using Propensity Score Methods to Create Target Populations in Observational Clinical Research. JAMA. 2020 Feb 4;323(5):466-467. doi: 10.1001/jama.2019.21558. No abstract available. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	overall survival	The primary outcome was overall survival (OS), which was defined as the time interval from the pediatric glioma diagnosis until death or the end of follow-up in SEER registry	2000.01-2018.12
Primary	overall survival	The primary outcome was overall survival (OS), which was defined as the time interval from the pediatric glioma diagnosis until death or the end of follow-up in Chinese registry	2010.01-2018.12